Skip directly to site content Skip directly to search


Español  Other Languages


Centers for Disease Control and Prevention. CDC twenty four seven. Saving Lives, Protecting People
 Search

		Submit


Tuberculosis (TB)








Targeted Testing, 2020										Related Pages
										Table of Contents
Table 1. Persons sought, enlisted, or registered for targeted testing projects
Figure 1. Persons who sought, enlisted, or registered for targeted testing by treatment disposition
Table 2. Persons who are diagnosed with latent TB infection (LTBI), by risk type and by initial and final treatment regimen
Table 3. Reasons for stopping treatment for persons identified with latent TB infection (LTBI) through targeted testing
Evaluation Indices, 2020
Table 4. Targeted testing evaluation indices
Table 5. Targeted testing evaluation indices, by risk type

Targeted testing is an effective prevention strategy for reducing the morbidity and mortality of tuberculosis (TB) disease in the United States. Targeted testing is used to identify and treat persons infected with M. tuberculosis. Identifying and treating persons who have latent infection (LTBI) is important as an estimated 80% of US TB cases are believed to be the result of longstanding, untreated LTBI.[1]
Beginning in 2020, CDC-funded state and city TB programs with ≥150 TB cases are required to submit targeted testing data (as outlined in the cooperative agreements). TB programs report results of their targeted testing activities to CDC by entering the data into the Aggregate Reports for Tuberculosis Program Evaluation (ARPE) form through the National Tuberculosis Indicators Project (NTIP) performance-monitoring tool. This report summarizes 2020 targeted testing data and is the first report summarizing this information.
Because targeted testing reporting includes treatment outcomes, final reporting extends over a 12-month period. For example, this means that individuals with TB infection identified in December 2020 would have until December 2021 to finish treatment, and the data would then be reported in 2022.
**Targeted testing data are submitted using the following 3 categories:**
**Project:** testing for groups done at sites outside the health department, as determined by the needs or convenience of the groups being tested. Testing projects might be held once, or they might be recurrent (e.g., annual testing at a correctional facility) or ongoing (e.g., testing of all new admissions to a homeless shelter).
**Individual:** testing for individuals or groups that occurs outside of testing projects; testing is often done at a health department clinic.
**Administrative:** testing for LTBI that is done when testing is a low public health priority because the tested persons or groups are not at risk for TB and might not be candidates for LTBI treatment. This testing is often required by regulations or policies created outside the TB control program.[2]
The number submitted in each category indicates the number of individuals the program classified under that category.
The following states and cities were required to report targeted testing data in 2020 because they had >150 TB cases in 2019: California, Georgia, Florida, Illinois, Los Angeles, Maryland, Massachusetts, New Jersey, New York, New York City, North Carolina, San Diego, Texas, Virginia, and Washington. Not all these states and cities reported or reported fully, and no TB programs with <150 cases reported targeted testing activities in 2020.”Targeted Testing, 2020
Data shown in tables and figures are up to date as of August 2, 2022.
**Table 1. Persons sought, enlisted, or registered for targeted testing**
Appendix A. Counts and Indices for Investigation of Sputum AFB Smear-Positive TB Cases, 2015-2019
Targeted testing project*
Targeted testing individual†
Administrative§
TotalSought, enlisted, or registered
14,152
4,056
5,230
**23,438***U.S.–born¶*
*9,936*
*96*
*201*
***10,233****Non-U.S.–born¶*
*1,567*
*397*
*124*
***2,088***Evaluated
13,810
3,591
4,198
***21,599****TST¶*
*160*
*>65*
*2,224*
***2,449****IGRA¶*
*12,122*
*453*
*385*
***12,960***TB disease
5
27
24
**56**Latent TB infection
1,393
1,324
452
**3,169****Note.** Programs reporting include California, Los Angeles, San Diego, Florida, Georgia, New Jersey, New York, North Carolina, and Virginia.
*Targeted testing project: Usually, testing projects for groups are done at sites outside the health department, as determined for the convenience or by the needs of the groups being tested. Such testing projects might be done only once during a limited period, or they might be recurrent (e.g., annual testing at a correctional facility) or ongoing (e.g., testing of all new admissions to a homeless shelter).
†Targeted testing individual: The sum of testing that is done one person at a time or by group but outside of testing projects, when testing is in accordance with national, state, or local guidelines for selecting persons who are at risk for TB and who are expected to be candidates for treatment if they have LTBI. The testing is often done at a health department clinic.
§Targeted testing administrative: Testing for LTBI that is done when testing is a low public health priority because the tested persons or groups are at low risk for TB and might not even be candidates for LTBI treatment. This testing often is required by regulations or policies created outside the TB control program.
¶Optional reporting fields.Top of Page**Figure 1. Persons who sought, enlisted, or registered for targeted testing by treatment disposition**
Figure 1. Persons who sought, enlisted, or registered for targeted testing by treatment dispositionTop of Page**Table 2. Persons diagnosed with latent TB infection (LTBI), by risk type and by starting and completing treatment regimen**
Table 3: Contact Investigation Evaluation Indices, Smear-Positive Cases
Targeted testing project medical risk*
Targeted testing project population risk†
Targeted testing individual medical risk*
Targeted testing individual population risk†
Administrative
TotalLatent TB infection
14
1,379
216
1,108
452
**3,169**Candidates for treatment
12
1,025
180
949
402
**2,568**Started treatment
12
451
140
622
253
**1,478**Completed treatment
10
351
110
458
163
**1,092****Note.** Programs reporting include California, Los Angeles, San Diego, Florida, Georgia, New Jersey, New York, North Carolina, and Virginia.
* Medical risk: Persons with LTBI who have a condition that has been associated with predisposition to TB disease, usually a concurrent medical diagnosis. LTBI treatment has increased urgency for persons in this target category.
† Population risk: Persons with LTBI who are members of socially or demographically defined groups that have been associated with high prevalence of TB infection or a high transmission rate.Top of Page**Table 3. Reasons patient stopped treatment for persons identified with latent TB infection (LTBI) through targeted testing**
Table 5: Reasons Contacts Stopped LTBI Treatment – Smear-Negative, Culture-Positive Cases
Targeted testing project
Targeted testing individual
Administrative
TotalContacts stopping treatment (n)
34
158
69
**261**Active TB developed
0
0
0
**0**Adverse effect of medicine
3
16
6
**25**Death
0
0
1
**1**Patient chose to stop
5
43
26
**74**Patient lost to follow-up
25
92
33
**150**Patient moved (follow-up unknown)
1
7
3
**11****Note.**Programs reporting for each project type include:
Targeted testing project: Los Angeles, San Diego, Florida, New Jersey, New York, and North Carolina.
Targeted testing individual: Florida, New York, North Carolina
Administrative: Florida, New York, North Carolina
Top of PageEvaluation Indices, 2020
**Table 4. Targeted testing evaluation indices**
Table 6: Contact Investigation Evaluation Indices – Smear-Negative, Culture-Positive Cases
Targeted testing project
Targeted testing individual
AdministrativeEvaluation %
97.6
88.5
80.3Disease %
0.0
0.8
0.6Latent TB infection %
10.1
36.9
10.8**Note.** Programs reporting include California, Los Angeles, San Diego, Florida, Georgia, New Jersey, New York, North Carolina, and Virginia.Top of Page**Table 5. Targeted testing evaluation indices, by risk type**
Table 7: Counts of Contacts, Other Cases
**Targeted testing project medical risk***
**Targeted testing project population risk†**
**Targeted testing individual medical risk***
**Targeted testing individual population risk†**
**Administrative**Candidate %
85.7
74.3
83.3
85.6
88.9Treatment %
100
44.0
77.8
65.5
62.9Completion%
83.3
77.8
78.6
73.6
64.4**Note.** Programs reporting include California, Los Angeles, San Diego, Florida, Georgia, New Jersey, New York, North Carolina, and Virginia.
* Medical risk: Persons with LTBI who have a condition that has been associated with predisposition to TB disease, usually a concurrent medical diagnosis. LTBI treatment has increased urgency for persons in this target category.
† Population risk: Persons with LTBI who are members of socially or demographically defined groups that have been associated with high prevalence of TB infection or a high transmission rateTop of Page
							
					
							Last Reviewed:  March 9, 2023						Source: 	Division of Tuberculosis Elimination, National Center for HIV, Viral Hepatitis, STD, and TB Prevention, Centers for Disease Control and Prevention
					Facebook
        Twitter
        LinkedIn
        Syndicate homeTuberculosisBasic TB Factsplus iconHow TB SpreadsLatent TB Infection and TB DiseaseSigns & SymptomsTB Risk FactorsExposure to TBTB PreventionVaccinesTB & HIV CoinfectionTB and DiabetesTB TermsPersonal StoriesTesting & Diagnosisplus iconWho Should be TestedTesting for TB InfectionTesting in BCG-Vaccinated PersonsTB Screening and Testing of Health Care PersonnelTesting During PregnancyDiagnosing latent TB infection and TB diseaseTreatmentplus iconDeciding When to Treat Latent TB InfectionTreatment Regimens for Latent TB Infection (LTBI)Treatment for TB DiseaseAdverse EventsTB Treatment of Persons Living with HIVTB Treatment and PregnancyTB Treatment for ChildrenFrequently Asked QuestionsDrug-Resistant TBResearchplus iconTB Epidemiologic Studies Consortiumplus iconResearch ProjectsPublicationsTB Trials Consortiumplus iconStudy DescriptionsBackgroundBehavioral & Social Science ResearchHealth Care Settingsplus iconTB Infection Control in Health Care SettingsResources for TB Screening and Testing of Health Care Personnelplus iconFrequently Asked QuestionsTB in Specific Populationsplus iconHealth DisparitiesAsian PersonsBlack or African American PersonsHispanic or Latino PersonsChildrenPregnancyCorrectional FacilitiesPeople Experiencing HomelessnessInternational TravelersLaboratory Informationplus iconDrug Susceptibility TestingFalse-Positive Investigation ToolkitInterim Laboratory Biosafety Guidance for XDR  tuberculosis strainsModel Performance Evaluation Program (MPEP)Rapid Molecular Testing to Detect Drug-Resistant TB in the USplus iconExecutive SummaryIntroductionBackground on Tests for Molecular Detection of DRGeneral Considerations and Principles for a Molecular DR Testing ServicePossible Scenarios and Scope of Testing for a Molecular DR Testing ServiceResearch NeedsGeneral Recommendations of the Expert PanelCommunication Plan for the ReportRecommendationsReferencesPanel Members and CDC ParticipantsAppendix 1Appendix 2Appendix 3The Uses of Nucleic Acid Amplification Tests for the Diagnosis of TBplus iconGeneral ConsiderationsGeneral Recommendations of the Expert PanelRecommendations to ACET, CDC, DTBEData & Statisticsplus iconTB Incidence in the United StatesReported TB in the US, 2022 Surveillance Reportplus iconNational DataReporting Area DataRisk FactorsDemographicsTB Treatment and Case OutcomesDrug-Resistant TBMolecular SurveillanceTuberculosis in the United States, 2022 (Slide Set)Archived Surveillance Reports and Slide Sets2021 State and City ReportArchived State and City ReportsProfessional Resources & Toolsplus iconTools for Healthcare ProvidersResources for TB Programsplus iconStrengthening Civil Surgeons’ Capacity to Improve LTBI Surveillance and Outcomes Among Status AdjustersNotice of Funding Opportunity (NOFO)Program EvaluationTB Centers of ExcellenceTB Elimination AllianceTB Genotypingplus iconConventional TB GenotypingWhole Genome SequencingTB GIMSAnalytic ToolsLatent Tuberculosis Infection ResourcesPublications & Productsplus iconPatient and Public MaterialsFact SheetsGuidelinesplus iconControl & EliminationDrug-Resistant TBInfection Control & PreventionLaboratory & GenotypingTB & HIVTB in Specific PopulationsTesting & DiagnosisTreatmentVaccines & ImmunizationsArchived TB GuidelinesGuides & Toolkitsplus iconAggregate ReportsCDC TB Surveillance TrainingCore CurriculumEffective TB Interviewing for Contact InvestigationEthnographic GuidesFalse-Positive Investigation ToolkitForging Partnerships to Eliminate TuberculosisGuide to Application of GenotypingLTBI: A Guide for Primary Health Care ProvidersMantoux Tuberculin Skin Testing ProductsReport of Verified Case of Tuberculosis (RVCT)Self-Study ModulesTB Contact Investigation Interviewing Skills CourseTB eDOT ToolkitUnderstanding the TB Cohort Review ProcessNewslettersplus iconTB Notes, No. 4, 2023TB Notes, No. 3, 2023TB Notes. No. 2, 2023TB Notes. No. 1, 2023TB Notes, No. 4, 2022TB Notes, No. 3, 2022TB Notes, No. 2, 2022TB Notes, No. 1, 2022TB Notes, No. 4, 2021TB Notes, No. 3, 2021TB Notes, No. 2, 2021TB Notes, No. 1, 2021Pamphlets, Brochures, Bookletsplus iconQuestions and AnswersPatient Education SeriesTuberculosis - Get the FactsTuberculosis - The Connection between TB and HIV12-Dose Regimen for Latent TB Infection-Patient Education BrochurePostersplus iconMantoux Tuberculin Skin Test Wall ChartWorld TB DayThink TBStop TBTake on TBReports & Articlesplus iconDTBE Authored Journal ArticlesTuberculosis Laboratory Aggregate ReportsSlide Setsplus iconIntroduction to TuberculosisEpidemiology of Tuberculosis Among Non-U.S.​–Born Persons in the United States, 1993–2016Self-Study Modules on Tuberculosis, 1-5 Slide SetsThe Tuberculosis (TB) in Correctional Settingsplus iconFacilitator GuideIntroduction to TB GenotypingEpidemiology of Tuberculosis in Correctional Facilities, United States, 1993-2017Prevention and Control of Tuberculosis in Correctional and Detention FacilitiesGuidelines for Preventing the Transmission of M. TB in Health care SettingsInvestigation of Contacts of Persons with Infectious TBEpidemiology of Pediatric Tuberculosis in the United StatesTargeted Tuberculosis Testing and Treatment of Latent Tuberculosis InfectionElectronic Tools & ResourcesWeb-Based Courses & Webinarsplus iconTB 101 for Health Care WorkersContent SyndicationInfographicsplus iconSocial Media GraphicsCustomizable Take on TB Infographic with InstructionsEventsWorld TB Dayplus iconU.S. TB ChampionsHistoryFeaturesplus iconTB Risk FactorsTreating Latent TB Infection with Short-Course RegimensWorld Tuberculosis (TB) Day 2021World Tuberculosis (TB) Day 2020Linksplus iconState TB Control OfficesAbout Usplus iconMission Statement and Activitiesplus iconDTBE Strategic PlanNational TB Program ObjectivesOrganization ChartAdvisory Groupsplus iconFederal TB Task Force To receive email updates about this page, enter your email address: Email Address			What's this?				Submit


About CDC
					Contact Us
					800-232-4636
 Facebook Twitter Instagram LinkedIn Youtube Pinterest Snapchat
 CONTACT CDC
				Contact Us
							Call 800-232-4636
							Email Us
			ABOUT CDC
				About CDC
							Jobs
							Funding
			POLICIES
				Accessibility
							External Links
							Privacy
							Policies
							No Fear Act
							FOIA
							OIG
							Nondiscrimination
							Vulnerability Disclosure Policy
			CONNECT WITH US
				Facebook
								Twitter
								Instagram
								LinkedIn
							Youtube
								Pinterest
								Snapchat
								Email
			LANGUAGES
				Español
							繁體中文
							Tiếng Việt
							한국어
							Tagalog
							Русский
							العربية
							Kreyòl Ayisyen
							Français
							Polski
							Português
							Italiano
							Deutsch
							日本語
							فارسی
							English


U.S. Department of Health & Human Services
			Accessibility
			External Links
			Privacy
			Policies
			No Fear Act
			FOIA
			Nondiscrimination
			OIG
			Vulnerability Disclosure Policy
			USA.gov


Exit Notification / Disclaimer Policy Close
 Links with this icon  indicate that you are leaving the CDC website. The Centers for Disease Control and Prevention (CDC) cannot attest to the accuracy of a non-federal website.
				Linking to a non-federal website does not constitute an endorsement by CDC or any of its employees of the sponsors or the information and products presented on the website.
				You will be subject to the destination website's privacy policy when you follow the link.
				CDC is not responsible for Section 508 compliance (accessibility) on other federal or private website. Website Disclaimers
 Cancel Continue